Skip to Main content Skip to Navigation
Journal articles

Serum GFAP in multiple sclerosis: correlation with disease type and MRI markers of disease severity

Abstract : Neurofilament light chain (NfL) has been demonstrated to correlate with multiple sclerosis disease severity as well as treatment response. Nevertheless, additional serum biomarkers are still needed to better differentiate disease activity from disease progression. The aim of our study was to assess serum glial fibrillary acid protein (s-GFAP) and neurofilament light chain (s-NfL) in a cohort of 129 multiple sclerosis (MS) patients. Eighteen primary progressive multiple sclerosis (PPMS) and 111 relapsing remitting MS (RRMS) were included. We showed that these 2 biomarkers were significantly correlated with each other (R = 0.72, p < 0.001). Moreover, both biomarkers were higher in PPMS than in RRMS even if multivariate analysis only confirmed this difference for s-GFAP (130.3 ± 72.8 pg/ml vs 83.4 ± 41.1 pg/ml, p = 0.008). Finally, s-GFAP was correlated with white matter lesion load and inversely correlated with WM and GM volume. Our results seem to confirm the added value of s-GFAP in the context of multiple sclerosis.
Complete list of metadata

Cited literature [22 references]  Display  Hide  Download
Contributor : Myriam Bodescot Connect in order to contact the contributor
Submitted on : Wednesday, July 22, 2020 - 1:35:07 PM
Last modification on : Friday, September 9, 2022 - 10:20:08 AM
Long-term archiving on: : Tuesday, December 1, 2020 - 4:42:57 AM


Publication funded by an institution


Distributed under a Creative Commons Attribution 4.0 International License




Xavier Ayrignac, Emmanuelle Le Bars, Claire Duflos, Christophe Hirtz, Aleksandra Maleska Maceski, et al.. Serum GFAP in multiple sclerosis: correlation with disease type and MRI markers of disease severity. Scientific Reports, Nature Publishing Group, 2020, 10 (1), pp.10923. ⟨10.1038/s41598-020-67934-2⟩. ⟨inserm-02904593⟩



Record views


Files downloads